{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit could not be calculated from the data due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"3.6","upperLimit":"NA","value":"18.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Tumor assessment was performed using RANO criteria for Participants with LGG.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Low Grade Glioma.","id":"OG000","title":"Low Grade Glioma"}],"paramType":"MEDIAN","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug. For phase II, only one tumor type cohort was opened (LGG).","reportingStatus":"POSTED","timeFrame":"From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)","title":"PFS as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)","type":"PRIMARY","unitOfMeasure":"Months"}